We noticed you are on our US page. Want to switch regions? Choose from the options:

LIlly JZJX

LIBRETTO-432:A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in patients with Stage IB-IIIA RET fusion-Positive NSCLC

Trial overview

Topic

LIlly JZJX

Description

Study J2G-MC-JZJX (JZJX) is a global, multicenter, randomized (1:1), double-blind, Phase 3 study comparing the efficacy and safety of selpercatinib twice daily (BID) (160 mg BID for participants ≥50 kg; 120 mg BID for participants <50 kg) to placebo in participants with RET fusion-positive Stage IB-IIIA NSCLC following completion of therapies with a curative intent; e.g. definitive locoregional treatment (such as surgery or radiotherapy) and applicable adjuvant chemotherapy, as determined by the investigator.

Physicians

Contact

Florida East Coast - Aventura

Peggy Mouradian & Nancy Joseph